Hasbrouck Heights, N.J. – April 9, 2008 – Zymes LLC announced that PTS, the lead compound of their Ubisol-Aqua™ solubilization technology, allows reactions to be performed in water at room temperature with yields and selectivity comparable to, or better than, those previously obtained in organic solvents. These new environmentally responsible chemical processes utilizing Zymes’ patented Ubisol-Aqua™ technology were published online in the American Chemical Society journal Organic Letters on March 12, 2008. Dr. Bruce Lipshutz, Professor of Organic Chemistry at the University of California Santa Barbara, demonstrated that the use of Zymes’ PTS can be applied to three diverse types of widely used chemical reactions (Suzuki–Miyaura biaryl couplings, Heck reactions, and intermolecular olefin cross-metathesis) that now proceed with water-insoluble materials, with water as the only solvent.

Industrial reactions are usually run in organic solvents at elevated temperatures. Commonly used organic solvents such as toluene, methylene chloride (DCM), dimethylformamide (DMF) and tetrahydrofuran (THF) can be toxic, flammable and expensive. During the reaction phase of a chemical manufacturing process, approximately 10 kilograms of organic solvents are required for every kilogram of product formed. Thus, in a single process scaled to 25 metric tons, the use of Zymes’ PTS could potentially replace 250 metric tons of organic solvents with pure water. Every year more than 3.2 billion kilograms of organic solvents are used in chemical manufacturing. The use of Zymes’ PTS, at a mere 1% penetration in the reaction phase of the chemical manufacturing process, could result in a reduction of more than 16 million kilograms of organic solvents.

Prof. Lipshutz stated “The significance of the PTS technology to green chemistry is that it not only opens doors to new reactions in water, but it decreases reliance on solvents, many of which are derived from the world’s oil supply. These processes also have the potential to reduce energy consumption and decrease solvent waste. To further enable such fundamental processes as Nobel Prize winning metathesis chemistry with “green” virtues is very gratifying.”

The US Environmental Protection Agency describes green chemistry as involving environmentally friendly chemicals and processes that result in: reduced waste; decreased costly clean-up treatments; safer processes based on water as solvent; and reduced demands on energy and resources. It is a preventive philosophy looking to put a stop to pollution at its source by encouraging the design of products and processes that reduce or eliminate the use and/or generation of environmentally hazardous compounds, including organic solvents. Zymes PTS provides a means to reduce this waste and decrease cost by facilitating the reactions in water at room temperature.

Research quantities will be available through Zymes’ exclusive distributor, Sigma-Aldrich (NASDAQ: SIAL), in May 2008 under catalog number 698717. Larger quantities are available under license by Zymes LLC.

“We are pleased to offer PTS pre-dissolved in water to the scientific community,” commented Dr. Steve Branca, Vice President of Business Development for Sigma-Aldrich. “We see PTS as an enabling technology that provides a multitude of options for effecting both chemical and biochemical processes with lipophilic compounds in water without recourse to co-solvents or heating.”
About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Its biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 36 countries and has 7,900 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit its award-winning website at http://www.sigma-aldrich.com.

About Zymes: Zymes LLC is a bioscience company based in Hasbrouck Heights, NJ that provides innovative solutions to its partners and consumers through proprietary science and technology, enabling new products to enhance the well-being of people and the environment. For more information visit its award-winning website at http://www.zymes.com or email info@zymesllc.com.

Greg Paddon-Jones received his PhD  in synthetic organic chemistry from The University of Queensland in Australia in 1998.  He began his scientific career as a post-doctoral fellow at Zeneca Agrochemicals located at, Heriot Watt University in Edinburgh, Scotland.  He then relocated to France to complete a second post doctoral fellowship, focusing on surfactant properties and chemistry as part of a collaboration between Condea Chemie GmbH and the Centre National de la Recherche Scientifique in Strasbourg.

Greg then transitioned to Lonza AG, a Swiss-based life science company and leading custom manufacturer of fine chemicals, intermediates, APIs and biopharmaceuticals. His primary assignments were in the field of applied research and development and optimization of chemical processes.  He was then appointed to the position of plant manager in a cGMP production facility, where he oversaw some of the most important manufacturing projects of Lonza. In his subsequent assignment as process excellence expert he specialized in process optimization using the Lean and Six Sigma toolboxes to improve chemical, manufacturing and business processes. His work led to significant productivity increases and project streamlining.

In February 2008, Greg joined the Zymes team as a Director of Technology Development.

Zymes is a bio-science company that combines science, technology, and nature to create products that improve your quality of life.

Zymes’ mission is to provide innovative solutions to our partners and consumers through our proprietary science and technology, enabling new products to enhance the well-being of people and our environment.
About Zymes: Zymes LLC holds substantial intellectual property ranging from the synthesis of coenzyme Q10 to drug delivery systems. With an arsenal of exciting new, cutting-edge technologies and products, the executive team at Zymes looks forward to bringing to market exciting new products resulting from our scientific programs and productive alliances with industry partners.

Ben received this very prestigious award, given to only 15-20 graduate students each year, based on the nomination of his Ph.D. thesis advisor, two additional letters of recommendation, his curriculum vitae, list of publications and awards, and an essay describing his original research in organic chemistry. Evidence of achieving innovative research is an important factor in the selection process. Ben will receive a $24,000 stipend toward his studies and will travel to the 2007 National Organic Symposium at Duke University in Durham, NC to present a poster detailing his work.

The Division of Organic Chemistry awards the fellowships to outstanding third and fourth year graduate students in organic chemistry. Nominations are received in the spring of each year. Potential candidates should visit the ACS Organic Chemistry Division site at http://organicdivision.org/fellowships.html for more information.

About Zymes:

Zymes LLC is a bioscience company that combines science, technology and nature to create products that improve the quality of life. It is dedicated to contributing to the well-being of individuals by developing high-quality products that provide significant, clinically-proven health and beauty benefits to consumers. Based in Hasbrouck Heights, NJ, Zymes holds substantial intellectual property ranging from production of synthetic CoQ₁₀ to pharmaceutical drug delivery systems. For more information see www.zymes.com.

Hasbrouck Heights, N.J. – Zymes LLC announced that the results from this study are being presented this week at the 2007 Meeting of the International Aids Society in Sydney, Australia.

Dr. Catherine L. Cherry and colleagues of the Burnet Institute, Melbourne, Australia studied the safety and effectiveness of coenzyme Q10 for use in reducing the neurological toxicity of HIV drugs in laboratory models of drug-induced nerve damage.

Nucleoside reverse transcriptase inhibitors (NRTIs) effectively inhibit replication of HIV and are central to effective HIV therapy. However, this class of drugs is potentially harmful to normal cells and can lead to serious side effects including wasting away of fat tissue and metabolic disturbances in people living with HIV on long-term anti-viral therapy. Two of the NRTIs that are still in clinical use (stavudine and didanosine) can cause nerve damage, leading to long-term pain in the feet (neuropathy). This neuropathy is one of the most common problems suffered by people living with HIV.

Dr. Cherry stated, “The treatment of patients with nutrients such as coenzyme Q₁₀ has shown promise in the prevention and treatment of nerve damage in other neurological diseases and has been suggested as a possible way to reduce the nerve toxicity of these antiviral drugs. Until now, we could not study coenzyme Q10 in the laboratory because it is insoluble in water. Zymes’ Ubisol-Aqua™: Coenzyme Q₁₀, a water-soluble formulation of coenzyme Q₁₀, allows us to study this nutrient in our laboratory model of nerve damage caused by these HIV drugs.”

In Dr. Cherry’s study, nerve cells from rats were first grown in the presence of Ubisol-Aqua™: Coenzyme Q₁₀ alone. They were then grown in the presence of Ubisol-Aqua™: Coenzyme Q₁₀ plus stavudine and Ubisol-Aqua™: Coenzyme Q₁₀ plus didanosine. The subsequent growth and survival of the nerve cells were measured using video image analysis.

In these studies, Ubisol-Aqua™: Coenzyme Q₁₀ alone was associated with significantly increased nerve cell growth and survival. Nerve cells grown with Ubisol-Aqua™: Coenzyme Q₁₀ survived at least one week longer than those grown without this compound. When nerve cells were grown in the presence of the HIV drugs stavudine or didanosine alone, nerve cell growth and survival was significantly impaired. However, when Ubisol-Aqua™: Coenzyme Q₁₀ was added to either stavudine or didanosine, the toxicity of the drugs was greatly reduced. After 19 days, nerve cells grown with Ubisol-Aqua™: Coenzyme Q₁₀ plus the drug stavudine grew and survived like normal nerve cells, whereas cells exposed to stavudine alone were not growing well. After only 6 days, nerve cells grown with didanosine alone were dying, but the nerve cells grown with Ubisol-Aqua™: Coenzyme Q₁₀ and didanosine grew and survived like normal nerve cells.

Dr. Cherry stated, “These data support the possibility that Ubisol-Aqua™: Coenzyme Q₁₀ may be useful for preventing the nerve damage associated with stavudine and didanosine. Controlled trials are needed to confirm this in a clinical setting and to examine the possible role of coenzyme Q₁₀ in treating established nerve damage”.

“Achieving water solubility of coenzyme Q₁₀ with our Ubisol-Aqua™ technology finally makes it possible to deliver coenzyme Q₁₀ in a form that improves its functionality.” said Dr. Randi Fain, Co-founder and Executive Vice President of Zymes LLC, New Jersey, USA “We believe the technology can enhance the health benefits of coenzyme Q₁₀ as well as other vitamins, nutrients and medicines to improve the quality of life for patients.”

To achieve solubilization, Ubisol-Aqua™ uses both complexation and reduced particle size. Through this combined approach, Zymes delivers previously water-insoluble drugs, nutrients, and other compounds as micelles of nanometer size offering many advantages over existing solubilization technologies. Ubisol-Aqua™, a pioneering nanotechnology, therefore makes possible the solubilization and reformulation of water-insoluble biologically active ingredients that would otherwise be commercially and clinically unavailable.

Zymes offers its delivery system technology to industry partners in need of more effective ways of making their ingredients water-soluble and potentially more bioavailable.

About Zymes: Zymes LLC is a bioscience company that combines science, technology and nature to create products that improve the quality of life. It is dedicated to contributing to the well-being of individuals by developing high-quality products that provide significant, clinically-proven health and beauty benefits to consumers. Based in Hasbrouck Heights, NJ, Zymes holds substantial intellectual property ranging from production of synthetic CoQ₁₀ to pharmaceutical drug delivery systems. For more information see www.zymes.com.

March 12 2007 – Zymes LLC announced that it has successfully solubilized fish oil and Omega-3 fatty acids (DHA/EPA/ALA). Zymes’ solubilization technology, Ubisol-Aqua™, provides a superior platform for solubilizing omega-3 fatty acids and other water-insoluble lipophilic compounds for foods, beverages, nutritional supplements, pharmaceuticals and cosmetics. The technology, available for licensing, provides improved solubility, enhanced bioavailability and particle size reduction to the nanometer level. Zymes new water-soluble formulation of omega-3 fatty acids is another major breakthrough for the many industries looking to supplement their products with functional ingredients.

To achieve solubilization, Ubisol-Aqua™ uses nanotechnology and complexation to reformulate and improve solubility of drugs, nutrient and cosmetic ingredients that are water-insoluble and therefore difficult for the human body to absorb. Using this combined approach, Zymes delivers new water-soluble omega-3 fatty acids with an average particle size of 34 nanometers.

“Achieving solubility of fish oil and omega-3 fatty acids creates additional opportunities to bring our Ubisol-Aqua™ technology to the food, beverage and nutritional markets around the world” said Benjamin D. Mamola, Co-founder and Executive Vice President of Global Business Development at Zymes. “Our new breakthrough technology makes it possible to more effectively deliver omega-3 fatty acids in foods and beverages. We believe the technology will greatly enhance the health benefits of these products to consumers.

Zymes offers its delivery system technology to industry partners in need of more effective ways of making their ingredients water-soluble and thus more bioavailable.

About Zymes

Zymes LLC is a bio-science company that combines science, technology and nature to create products that improve the quality of life. It is dedicated to contributing to the well-being of individuals by developing high-quality products that provide significant, clinically-proven health and beauty benefits to consumers. Based in Hasbrouck Heights, NJ, Zymes holds substantial intellectual property ranging from production of synthetic coenzyme Q₁₀ to pharmaceutical drug delivery systems.

Zymes’ new H_QO^TM has an average particle size in water of 22 nanometers, 10 times smaller than those commercially available. It offers improved solubility, enhanced bioavailability, higher concentration and is available for licensing.

“Obtaining GRAS status for our water-soluble coenzyme Q₁₀, H_QO^TM, creates unlimited opportunities in food, beverage and nutritional markets around the world” said Benjamin D. Mamola, Co-founder and Executive Vice President of Global Business Development at Zymes. “Our new breakthrough technology finally makes it possible to deliver coenzyme Q₁₀ in everyday products like water, soft drinks, juices and many other types of foods, beverages and nutritional supplements.”

Zymes also offers its delivery system technology, Ubisol-Aqua^TM to industry partners seeking more efficient ways of making their insoluble or lipophilic ingredients water-soluble.

“The scientific data presented within our GRAS application indicates that PTS can safely provide solubility benefits,” said Randi Fain, MD, Co-founder and Executive Vice President of Clinical and Scientific Affairs. “Receiving the FDA’s positive response to our GRAS application is very important to our research efforts and validates the delivery system’s 14-year development process.”

About Zymes

Zymes LLC is a bio-science company that combines science, technology and nature to create products that improve the quality of life. It is dedicated to contributing to the well-being of individuals by developing high-quality products that provide significant, clinically-proven health and beauty benefits to consumers. Based in Hasbrouck Heights, NJ, Zymes holds substantial intellectual property ranging from production of synthetic coenzyme Q₁₀ to pharmaceutical drug delivery systems.

Nihan’s research is focused on coenzyme Q₁₀ (CoQ10) to determine whether coenzyme Q₁₀ is truly nature’s ideal vehicle for electron transport in our mitochondria. The research involves the first syntheses of new quinone-modified analogs of coenzyme Q₁₀. Nihan is also investigating a potential new drug delivery system for transporting anti-tumor agents, nucleosides, and other drugs for the treatment of various diseases.

Nihan brings a significant level of expertise that will support Zymes’ commitment to developing products and technologies that contribute to the well-being of individuals. She is pursuing her doctorate in organic chemistry at the University of California and has received honor and distinction at the University for her accomplishments.

About Zymes

Zymes LLC is a bio-science company that combines science, technology and nature to create products that improve the quality of life. It is dedicated to contributing to the well-being of individuals by developing high-quality products that provide significant, clinically-proven health and beauty benefits to consumers. Based in Hasbrouck Heights, NJ, Zymes holds substantial intellectual property ranging from production of synthetic coenzyme Q₁₀ to pharmaceutical drug delivery systems.

Volker joins Zymes with 10 years experience at the forefront of chemical and pharmaceutical research, process development, new business development and equity capital markets research. His experience includes positions at leading organizations including BASF AG, Deutsche Bank, GlaxoSmithKline and Stanford University.

Zymes will bring products to consumers that capitalize on the health and beauty benefits of coenzyme Q₁₀. Coenzyme Q_10, required by the body for energy production and as an antioxidant, is naturally produced in every cell of the body. However, its production in humans typically peaks by age 21 and declines thereafter. This has lead to an increase in public awareness of the value of dietary supplementation with this nutrient.

“Decades of research on coenzyme Q₁₀ lends strong support to its role in cellular energy production, as well as a naturally occurring antioxidant.” said Benjamin D. Mamola, Co-founder and Executive Vice President of Global Business Development at Zymes, LLC. “However, its poor bioavailability, due to its insolubility in water, limits its use in a broader range of applications. We are passionate about developing water-soluble coenzyme Q₁₀ products to enhance the benefits to consumers.”

After speaking at a lecture at Rutgers University in March of 1996 on the synthetic chemistry of Coenzyme Q_3-8, Dr. Bruce Lipshutz, professor of organic chemistry at the University of California, Santa Barbara, spent years of experimentation ultimately resulting in the “Lipshutz” method capable of synthesizing coenzyme Q₁₀. After Dr. Lipshutz secured exclusive rights to this intellectual property from the University of California, he formed a start-up company, Zymes, Inc. Patent applications were filed around the world and Dr. Lipshutz pursued the commercialization of his patented technology.

A phone call from New Jersey prompted a meeting took place in southern California with the team that would ultimately form the basis of a new company, Zymes, LLC. The team’s combined passion for bringing coenzyme Q₁₀ to the attention of the world was evident, and soon thereafter, the founding partners of Dr. Randi Fain, Mr. Benjamin D. Mamola, Prof. Bruce Lipshutz, and Mr. Vince Morano as CEO, launched Zymes LLC .

In addition to the patented “Lipshutz” method to produce coenzyme Q₁₀, the team has ambitious plans to deliver bioavailable water-soluble coenzyme Q₁₀ products. “We believe it is possible to significantly enhance delivery of coenzyme Q₁₀ and other nutraceuticals, as well as pharmaceuticals that, likewise, show poor water solubility. Our goal is to bring a technology to market that improves both solubility and bioavailability of compounds that contribute to the improvement of human health.” said Dr. Lipshutz, Executive Vice President of Research and Development at Zymes.

About Zymes

Zymes, LLC is a bio-science company that combines science, technology and nature to create products that improve the quality of life. It is dedicated to contributing to the well-being of individuals by developing high-quality products that provide significant, clinically-proven health and beauty benefits to consumers. Based in Hasbrouck Heights, NJ, Zymes holds substantial intellectual property ranging from production of synthetic coenzyme Q₁₀ to pharmaceutical drug delivery systems.

Dr. Ghorai will focus on the development of a “second generation” delivery system to complement Zymes’ existing water-solubilizing technology, UbiSol-Aqua™. UbiSol-Aqua™ uses nanotechnology and complexation to better solubilize and reformulate drug, nutrient and cosmetic ingredients.

“The implications of H_QO™, UbiSol-Aqua™ and related delivery system technologies to the human body are astounding” said Dr. Lipshutz, Co-founder and Executive Vice President of Research and Development at Zymes. “We are committed to ensuring that research continues to fuel advancements that will allow people to harness these powerful benefits.”

Dr. Ghorai received a Ph.D. in chemistry from the Indian Institute of Chemical Biology and will play an important role in helping Zymes further its mission to develop high quality products that provide significant health and beauty benefits to consumers. He has an impressive background in conducting breakthrough research.

About Zymes

Zymes, LLC is a bio-science company that combines science, technology and nature to create products that improve the quality of life. It is dedicated to contributing to the well-being of individuals by developing high-quality products that provide significant, clinically-proven health and beauty benefits to consumers. Based in Hasbrouck Heights, NJ, Zymes holds substantial intellectual property ranging from production of synthetic coenzyme Q₁₀ to pharmaceutical drug delivery systems.